Articles

Momentum stocks are coming off their best stretch of outperformance in years — since just before the financial crisis, in fact. That’s making some investors nervous.

Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.

Easter sales will total $22.4 billion in 2024, according to the National Retail Federation — a 7% decline from last year.

U.S. banks are struggling to keep up with evolving artificial-intelligence technology that has enabled fraudsters to easily impersonate customers and spread malware using AI-generated text, according to a report published Wednesday by the Treasury Department.

Higher office space vacancies trigger rise in criticized and modified loans, as a maturity wall looms

Merck’s stock rallied into record territory Wednesday, after the drug giant’s treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administration.

Tech stocks have been on a wild ride over the past few years, but the Franklin DynaTech Fund has performed very well over long cycles. Here’s how it might get in early on another transformational business cycle.

The problem isn’t a lack of controls, visibility or knowledge. It’s the lack of innovative thinking.

A growing ‘wall of worry’ that U.S. stocks are entering a period of irrational exuberance.

Traditional utilities are no match for upstart rivals seeking fast growth.

Mortgage applications dipped 0.7% in the last week, the Mortgage Bankers Association said. The average rate for a 30-year mortgage is 6.93%.

Much chatter has been devoted to what’s needed for the U.S. stock market rally to continue this year. A big one on the to-do list? Seeing gains spreading beyond the “Magnificent Seven” tech stocks, which themselves have not been moving in tandem.